中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2008年
2期
85-87
,共3页
李席如%马冰%王建东%刘洪一%李捷%郑一琼%张艳君%陈玉秋%晋援朝%李荣
李席如%馬冰%王建東%劉洪一%李捷%鄭一瓊%張豔君%陳玉鞦%晉援朝%李榮
리석여%마빙%왕건동%류홍일%리첩%정일경%장염군%진옥추%진원조%리영
乳腺肿瘤%药物疗法%联合%表阿霉素%多西他赛
乳腺腫瘤%藥物療法%聯閤%錶阿黴素%多西他賽
유선종류%약물요법%연합%표아매소%다서타새
Breast neoplasms%Drug therapy,combination%Pharmorubicin%Docetaxel
目的 评估多西他赛联合表阿霉素新辅助治疗乳腺癌的临床疗效和毒性反应.方法 2005年6月至2007年3月,94例经空芯针活检组织学诊断证实的乳腺癌患者在术前接受新辅助化疗,方案为多西他赛75 mg/m2(第1天)和表阿霉素80 mg/m2(第1天)静脉注射,每3周为1个周期,共2～4个周期,化疗后12～16 d行手术治疗.结果 原发病灶临床有效率为80%(76/94),其中临床完全缓解为22%(21/94),临床部分缓解为58%(55/94),疾病稳定为17%(16/94),疾病进展为2%(2/94),病理完全缓解为3%(3/94).常见的毒性反应有:中性粒细胞减少症,脱发和恶心呕吐.76例(80%)患者发生Ⅲ～Ⅳ度中性粒细胞减少症,4例发生3～4度血小板减少症,84例发生重度脱发.90例(95%)患者使用粒细胞集落刺激因子(G-CSF)支持治疗.无因新辅助化疗引起的败血症和死亡病例.结论 多西他赛联合表阿霉素的方案在新辅助治疗乳腺癌中疗效显著,耐受性较好.
目的 評估多西他賽聯閤錶阿黴素新輔助治療乳腺癌的臨床療效和毒性反應.方法 2005年6月至2007年3月,94例經空芯針活檢組織學診斷證實的乳腺癌患者在術前接受新輔助化療,方案為多西他賽75 mg/m2(第1天)和錶阿黴素80 mg/m2(第1天)靜脈註射,每3週為1箇週期,共2～4箇週期,化療後12～16 d行手術治療.結果 原髮病竈臨床有效率為80%(76/94),其中臨床完全緩解為22%(21/94),臨床部分緩解為58%(55/94),疾病穩定為17%(16/94),疾病進展為2%(2/94),病理完全緩解為3%(3/94).常見的毒性反應有:中性粒細胞減少癥,脫髮和噁心嘔吐.76例(80%)患者髮生Ⅲ～Ⅳ度中性粒細胞減少癥,4例髮生3～4度血小闆減少癥,84例髮生重度脫髮.90例(95%)患者使用粒細胞集落刺激因子(G-CSF)支持治療.無因新輔助化療引起的敗血癥和死亡病例.結論 多西他賽聯閤錶阿黴素的方案在新輔助治療乳腺癌中療效顯著,耐受性較好.
목적 평고다서타새연합표아매소신보조치료유선암적림상료효화독성반응.방법 2005년6월지2007년3월,94례경공심침활검조직학진단증실적유선암환자재술전접수신보조화료,방안위다서타새75 mg/m2(제1천)화표아매소80 mg/m2(제1천)정맥주사,매3주위1개주기,공2～4개주기,화료후12～16 d행수술치료.결과 원발병조림상유효솔위80%(76/94),기중림상완전완해위22%(21/94),림상부분완해위58%(55/94),질병은정위17%(16/94),질병진전위2%(2/94),병리완전완해위3%(3/94).상견적독성반응유:중성립세포감소증,탈발화악심구토.76례(80%)환자발생Ⅲ～Ⅳ도중성립세포감소증,4례발생3～4도혈소판감소증,84례발생중도탈발.90례(95%)환자사용립세포집락자격인자(G-CSF)지지치료.무인신보조화료인기적패혈증화사망병례.결론 다서타새연합표아매소적방안재신보조치료유선암중료효현저,내수성교호.
Objective To evaluate the clinical efficacy and toxicity of combination neoadjuvant chemotherapy with docetaxel and pharmorubicin in the treatment of locally advanced breast cancer.Methods From June 2005 to March 2007,94 breast cancer patients who have been pathologically confirmed by core needle biopsy were treated with neoadjuvant chemotherapy before operation.Docetaxel 75 mg/m2 plus pharmorubicin 80 mg/m2 were administered as intravenous infusion on the first day of each 3-week cycle.Accepted 2 to 4 cycles of the treatment,the patients were underwent surgery after 12 to 16 days.Results The overall response rate(RR)was 80%(76/94).The complete clinical response rate(CR)was 22%(21/94).The partial response rate(PR)was 58%(55/94).The stable disease(SD)rate was 17%(16/94).The progress disease(PD)rate was 2%(2/94).The pathological complete rate(pCR)was 3%(3/94).The major toxic reactions of the therapy were neutropenia,alopecia,nausea and vomit.76 patients (80%)suffered with grade 3 to 4 neutropenia.4 patients suffered with grade 3 to 4 thrombocytopenia.84 patients suffered with severe alopecia.90 patients(95%)accepted supportive treatment of G-CSF.Septicemia and death were not occurred in this study.Conclusion The combination neoadjuvant chemotherapy with docetaxel and pharmorubicin is an effective method to treat breast cancer and the toxicities are tolerable.
